The father of Linac: Jean﹒ Dr. Jean-Paul Perraudin
Dr. Jean-Paul Perraudin was born in France in October 1945. He holds a PhD in Science from the Free University of Brussels and a Master of Business Administration. Dr. Perraudin has been committed to breast milk research at the Belgian Human Milk Bank. From 1970 to 1983, he extracted lactoferrin, lactoperoxidase and lysosomal enzymes from breast milk. He is known as a pioneer in breast milk biological enzyme research.
Dr. Perraudin has been committed to lactoferrin research for more than 30 years. He has published more than 40 papers in many international academic journals and written 3 scientific books on lactoferrin research. He has 5 patented technologies. , has conducted in-depth research on lactoferrin and has rich experience in production and application.
Awards received
Won the "Best Scientific and Technological Innovation Award of the Year" from the Belgian government twice in 1979 and 1989
Scientific Footprint
In 1970, he began to study the activity and application of lactoferrin and lactoperoxidase;
In 1982, Petrofina Group applied Dr. Perraudin’s research results to the industrial production of lactoferrin from milk. and lactoperoxidase; under the guidance of Dr Perraudin and others, Oleofina cooperated with other companies in the veterinary field to develop products for the treatment of animal diarrhea and mastitis, and obtained a patent in 1985;
In 1985, a contract was signed with Japan's Morinaga Dairy Industry, and for the first time all the lactoferrin produced was used in Morinaga infant formula;
In 1987, BIOPOLE Biological Products Co., Ltd. was founded, and its products and technologies were used in Food, feed, cosmetics, oral care and other fields;
In 1994, it cooperated with Domo Food Ingredients Company to produce lactoferrin and lactoperoxidase;
In 2000 R&D and production of BioXtra (Bio-X Healthcare) oral care products;
In 2002, research on the food additive ADILA and the antimicrobial system catallix-lactoperoxidase (TMI EUROPE) was carried out;
In 2004, we cooperated with the Belgian company Belgomilk to produce lactoferrin and lactoperoxidase, and carried out clinical trials of lactoferrin in the treatment of hepatitis C;
In 2006, we launched lactoperoxidase Clinical trials of biological enzymes in the treatment of Helicobacter Pilori (Helicobacter pylori infection);
In 2007, Dr. Paladin developed a new patented purification technology to improve the quality of commercial lactoferrin, named "Lactoferrin-NFQ". Based on this new product, he decided to establish Taleden Laboratories to commercialize this product and create new finished products containing "Lactoferrin-NFQ".
In 2009, under the auspices of Dr. Paladin, Taladen Laboratory and Beijing Xinbaili Paladin Biotechnology Development Co., Ltd. developed a new generation of infant formula milk powder: Lenac infant formula milk powder, which will contain The highest quality lactoferrin formula milk powder was introduced to China for the first time.